IOL Chemicals Reports 90% Q1 Profit Growth Ahead of Q2

IOL Chemicals and Pharmaceuticals Limited reported net profit of ₹64.40 crore for Q1 FY27, up 89.80% from ₹33.93 crore a year earlier, while revenue rose 37.08% to ₹756.26 crore. IOL Chemicals & Pharmaceuticals is scheduled to report its Q2 FY27 results on October 30, 2026, following a quarter of higher sales and improved profitability.

What did IOL Chemicals & Pharmaceuticals report in Q1 FY27?

IOL Chemicals & Pharmaceuticals reported consolidated revenue of ₹756.26 crore in the quarter ended June 2026, compared with ₹551.69 crore in the corresponding quarter a year earlier. The reported year-on-year increase was 37.08%. Revenue was also 22.09% higher than ₹619.45 crore in the preceding quarter.

Net profit rose to ₹64.40 crore from ₹33.93 crore in the June 2025 quarter, representing 89.80% year-on-year growth. The company also reported a quarter-on-quarter net-profit increase of 21.14%. Gross profit was reported at ₹82 crore, up 13.81% sequentially and 93.89% from the year-earlier period.

The first-quarter earnings release reported earnings per share of ₹2.19, compared with ₹1.16 in Q1 FY26. It also put revenue at ₹7.64 billion and net income at ₹644.0 million, which are equivalent to about ₹764 crore and ₹64.4 crore respectively. The difference between the rounded revenue figures reflects the formats used in the disclosed material.

Profit margin was reported at 8.4%, compared with 6.2% in Q1 FY26. The earnings release said the margin improvement was driven by higher revenue. Other reporting on the quarter cited operational efficiency and diversification, with non-ibuprofen pharmaceutical products contributing 43% of pharmaceutical segment revenue.

When will IOL Chemicals & Pharmaceuticals announce Q2 FY27 results?

IOL Chemicals & Pharmaceuticals has announced October 30, 2026 as the date for its Q2 FY27 results. The quarter under review is the September 2026 quarter, following the company's June-quarter performance.

The company has also scheduled an analyst and investor conference call for November 2, 2026, at 11:30 AM IST to discuss Q2 and H1 FY27 financial results. The call is intended to allow shareholders and market participants to hear management's discussion of recent performance and outlook.

The announced results date is important because it follows a June quarter in which revenue and net profit reached five-quarter highs in the reported data. However, the supplied information contains no Q2 FY27 financial figures or company guidance specific to the September quarter.

How does the June quarter compare with recent performance?

IOL Chemicals & Pharmaceuticals entered FY27 after reporting FY26 revenue of ₹2,340.3 crore and net profit of ₹137.7 crore. The FY26 figures represented a 36.4% year-on-year rise in net profit, according to the reported results.

In Q4 FY26, revenue was reported at ₹621.2 crore, while net profit was ₹53.2 crore. Revenue increased 17.4% year-on-year in that quarter and net profit rose 68.2%. The Q1 FY27 revenue of ₹756.26 crore was therefore higher than the reported Q4 FY26 level.

The company had stated that it expected mid- to high-teens revenue growth in FY27 and was targeting EBITDA margins of 14% to 14.5%. These are company targets rather than reported Q2 FY27 outcomes. Investors will be able to compare the September-quarter numbers with these stated operating parameters once the results are released.

Earlier, IOL Chemicals & Pharmaceuticals reported Q2 FY26 revenue of ₹567.50 crore, EBITDA of ₹64.00 crore and profit after tax of ₹30.00 crore. That quarter included flood-related cost pressures, according to the reported results, providing context for the subsequent increase in revenue and profit.

What do the results mean for investors and operations?

The Q1 FY27 figures show that IOL Chemicals & Pharmaceuticals recorded faster growth in net profit than in revenue on a year-on-year basis. Revenue rose 37.08%, while net profit rose 89.80%, alongside an increase in reported profit margin to 8.4% from 6.2%.

For investors, the October 30 announcement will provide the next disclosed measure of whether the higher June-quarter sales and profitability were sustained in the September quarter. The scheduled November 2 conference call is the next formal opportunity for management to address the Q2 and first-half financial performance.

The reported contribution of non-ibuprofen products, at 43% of pharmaceutical segment revenue in Q1 FY27, is also relevant to the company's business mix. The available information does not provide a comparable segment contribution for the September quarter, so no conclusion can be drawn before the Q2 release.

Conclusion

IOL Chemicals & Pharmaceuticals delivered a stronger Q1 FY27, with revenue of ₹756.26 crore and net profit of ₹64.40 crore. The 37.08% increase in revenue, 89.80% increase in net profit and margin improvement to 8.4% were the central financial developments in the June 2026 quarter.

The next item to watch is the Q2 FY27 result scheduled for October 30, 2026, followed by the analyst and investor call on November 2 at 11:30 AM IST. The disclosures will show the September-quarter financial outcome and provide management's stated perspective on the first half of FY27.